Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (NYSE: PLX) | Delayed: 2.69 +0.08 (3.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.61 | 52 Week High | $1.11 | |||
| Open | $2.61 | 52 Week Low | $0.41 | |||
| Day High | $2.73 | P/E | N/A | |||
| Day Low | $2.58 | EPS | $-0.29 | |||
| Volume | 870,832 | |||||
| PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (NYSE: PLX) | Delayed: 2.69 +0.08 (3.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.61 | 52 Week High | $1.11 | |||
| Open | $2.61 | 52 Week Low | $0.41 | |||
| Day High | $2.73 | P/E | N/A | |||
| Day Low | $2.58 | EPS | $-0.29 | |||
| Volume | 870,832 | |||||
